Quick Takeaways
- This page summarizes Robert E. George's Form 4 filing for Moleculin Biotech, Inc. (MBRX).
- 1 reported transaction and 1 derivative row are listed below.
- Filing timestamp: 14 Nov 2025, 16:05.
Robert E. George - 12 Nov 2025 Form 4 Insider Report for Moleculin Biotech, Inc. (MBRX)
- Role
- Director
- Signature
- /s/ Jonathan Foster by Power of Attorney
- Issuer symbol
- MBRX
- Transactions as of
- 12 Nov 2025
- Net transactions value
- $0
- Form type
- 4
- Filing time
- 14 Nov 2025, 16:05:24 UTC
- Previous filing
- 06 Nov 2024
- SEC
- View on sec.gov
Quoteable Key Fact
"Robert E. George filed Form 4 for Moleculin Biotech, Inc. (MBRX) on 14 Nov 2025."
What Changed
- Previous filing in this sequence was filed on 06 Nov 2024.
- Current net transaction value: $0.
Why This Matters
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Source Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| George Robert E. | Director | C/O MOLECULIN BIOTECH, INC., 5300 MEMORIAL DR., SUITE 950, HOUSTON | /s/ Jonathan Foster by Power of Attorney | 14 Nov 2025 | 0001674701 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | MBRX | Stock Options (right to buy) | Award | +150,000 | +978% | 165,336 | 12 Nov 2025 | Common Stock | 150,000 | $0.4900 | Direct | F1, F2 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | The options set forth in this table vest on November 12, 2026, subject to the grantee's continued service on the Company's Board of Directors on each vesting date. |
| F2 | The options were issued in connection with the reporting person's Board of Director service to the Company. |